Physician profile
Debra Brown
NPI 1932107885
$2,679.45
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,130 · 2022: $1,068 · 2023: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $672.91 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $315.41 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $307.52 | 2021-2023 | Farxiga, Breztri, Lokelma |
| Astellas Pharma US INC | $212.18 | 2021 | |
| Glaxosmithkline, LLC. | $164.66 | 2021-2023 | Trelegy Ellipta |
| Abbott Laboratories | $148.29 | 2022-2023 | Freestyle Libre 2, Proclaim |
| Lilly USA, LLC | $98.48 | 2021-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.23 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.98 | 2022 | |
| Amgen INC. | $65.79 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $63.55 | 2021-2023 | Nuzyra |
| Mylan Specialty L.P. | $50.53 | 2022 | |
| Janssen Pharmaceuticals, INC | $49.91 | 2021-2023 | Xarelto |
| Abbvie INC. | $49.54 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $36.48 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $34.70 | 2021-2022 | |
| Daiichi Sankyo INC. | $29.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.14 | 2022 | |
| Merck Sharp & Dohme LLC | $19.59 | 2022 | |
| Exact Sciences Corporation | $18.94 | 2023 | Cologuard Collection Kit |
| Sun Pharmaceutical Industries INC. | $18.91 | 2021 | |
| Dexcom, INC. | $17.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.12 | 2021 | |
| Grifols USA, LLC | $16.94 | 2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.70 | 2022 | |
| Gilead Sciences, INC. | $15.28 | 2021 | |
| Nevro Corp. | $14.35 | 2022 | |
| Amarin Pharma, INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.